Protalix BioTherapeutics Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins, has appointed Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. To ensure a seamless transition, Mamlok has joined the company and is working alongside Rubin. After his tenure as Chief Financial Officer concludes, Rubin will remain available to the company as needed until ...